Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors

NCT07600476 is registered in ClinicalTrials.gov with Kupando GmbH as lead sponsor.

NCT NCT07600476
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07600476 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
Lead sponsor
Kupando GmbH
Phase
Phase 1
Overall status
Recruiting
Start date
July 3, 2026
Completion date
December 31, 2028
Enrollment
21 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

basal cell carcinoma of skin, cutaneous melanoma, cutaneous squamous cell carcinoma (cscc), merkel cell carcinoma of skin, mucosal melanoma